X

Trial Profile

A Phase I/II Study of TTI-621 in Combination With Doxorubicin in Patients With Unresectable or Metastatic High-Grade Leiomyosarcoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 16 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxorubicin (Primary) ; Ontorpacept (Primary)
Indications Leiomyosarcoma; Soft tissue sarcoma
Focus Adverse reactions; Therapeutic Use
Acronyms TTI-621-03
Sponsors Pfizer

Most Recent Events

28 Feb 2024 Status changed from active, no longer recruiting to discontinued.
20 Sep 2023 Planned End Date changed from 5 Feb 2024 to 24 Dec 2023.
20 Sep 2023 Planned primary completion date changed from 5 Feb 2024 to 24 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com